Edwards Lifesciences (EW) Asset Writedowns and Impairment (2017 - 2026)

Edwards Lifesciences' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $123.6 million for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $123.6 million in Q1 2026; TTM through Mar 2026 was $357.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $186.9 million, changed N/A from the prior year.
• Asset Writedowns and Impairment declined to $123.6 million in Q1 2026 per EW's latest filing, from $146.9 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $146.9 million in Q4 2025 and bottomed at $40.0 million in Q3 2025.